SPRING BANK PHARMACEUTICALS, INC. (NASDAQ:SBPH) Files An 8-K Other EventsItem 8.01 Other Events.
On July 10, 2017, Spring Bank Pharmaceuticals, Inc. (“Spring Bank”) issued a press release announcing that it had entered into a clinical trial supply and collaboration with Gilead Sciences, Inc. (“Gilead”).Under the terms of the arrangement, Gilead will fund and conduct a Phase 2 trial examining the use of Spring Bank’s oral selective immunomodulator, SB 9200, co-administered with Gilead’s Vemlidy® (tenofovir alafenamide) in patients infected with chronic hepatitis B virus.Spring Bank will supply SB 9200 for this clinical trial.A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press release dated July 10, 2017. |
Spring Bank Pharmaceuticals, Inc. ExhibitEX-99.1 2 sbph-ex991_6.htm PRESS RELEASE sbph-ex991_6.htm Exhibit 99.1 Spring Bank Announces Collaboration with Gilead for Hepatitis B (HBV) Phase 2 Study Exploring Combination Treatment of SB 9200 and Vemlidy® HOPKINTON,…To view the full exhibit click here
About SPRING BANK PHARMACEUTICALS, INC. (NASDAQ:SBPH)
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company’s SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. It also focuses on the use of SB 9200 in other viral diseases, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and latency and hepatitis delta virus (HDV), conducting preclinical research of additional SMNH product candidates or compounds as antiviral therapies and conducting early-stage research programs.
